WSA
PCRX icon

Wall Street Associates’s Pacira BioSciences PCRX Stock Holding History

Wall Street Associates’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,766
Closed -$1.36M – 261
2015
Q4 		$1.36M Buy
17,766
+5,828
+49% +$330K 0.38% 89
2015
Q3 		$491K Sell
11,938
-4,289
-26% -$263K 0.09% 222
2015
Q2 		$1.15M Sell
16,227
-3,858
-19% -$304K 0.11% 193
2015
Q1 		$1.78M Sell
20,085
-11,798
-37% -$1.2M 0.17% 155
2014
Q4 		$2.83M Sell
31,883
-2,207
-6% -$209K 0.27% 115
2014
Q3 		$3.3M Sell
34,090
-13,567
-28% -$1.32M 0.34% 104
2014
Q2 		$4.38M Sell
47,657
-5,100
-10% -$388K 0.38% 100
2014
Q1 		$3.69M Sell
52,757
-42,484
-45% -$2.89M 0.3% 112
2013
Q4 		$5.47M Sell
95,241
-235,370
-71% -$12.4M 0.45% 80
2013
Q3 		$15.9M Sell
330,611
-431,098
-57% -$15.7M 1.48% 7
2013
Q2 		$22.1M Buy
+761,709
New +$22M 2.25% 1

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wall Street Associates's PCRX Position: Q1 2016 in Review

Wall Street Associates sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 17,766 shares — an estimated $1.36M sold.

Wall Street Associates first reported a position in PCRX in Q2 2013 and held it in 11 quarters. The position peaked at $22.1M in Q2 2013. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • Wall Street Associates reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • Wall Street Associates sold 17,766 Pacira BioSciences shares in Q1 2016, an estimated $1.36M.
  • Wall Street Associates first reported a position in Pacira BioSciences in Q2 2013 and held it in 11 quarters.
  • Wall Street Associates's Pacira BioSciences position peaked at $22.1M in Q2 2013.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Wall Street Associates's 13F filing for Q1 2016, filed 13 May 2016.